Iran Press/Iran News: In an exclusive interview with Iran Press on Sunday, Mostafa Ghanei said the new Iranian medicine "Alsava" is for treatment of patients with Amyotrophic Lateral Sclerosis (ALS), a disease which results in the death of motor neurons in the brain and the spinal cord, leading to the gradual paralysis of the patient.
He went on to say that population aging increases the need for drugs that are specific to the nervous system, and the elderly population is growing in Iran.
"The next point is that these medicines were monopolized by some countries. Production of "Alsava" medicine in Iran as the second or third largest manufacturer, shows that our knowledge-based companies have achieved the complexities of modern drug technologies," he added.
The chairman of the Biotechnology Development Council further explained that there is no world-class medicine that cannot be produced in this country within a period of two years.
Mostafa Ghanei stressed: "Fortunately, the whole process of manufacturing the new drug, "Alsava", took just two years."
211/104
Read more:
knowledge-based companies, herald of promising atmosphere for academics: Minister
Share of Iran's knowledge-based medical equipment companies reaches 72 percent
